From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Buy Jim Mellon's Port Erin?

By Kelvin Prescott | Friday 20 May 2016


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Tom Winnifrith recently suggested that Port Erin Biopharma (PEBI) has gone limp because of pessimism about Plethora's premature ejaculation treatment. Cynical Bear says be suspicious of sub-scale investment companies on AIM, full of related party transactions and corporate overheads. So… obviously the moronic thing to do is pile in, right? But still, I am long Port Erin, at least when the price is right (sub 4p). Here’s why.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 10:41:25